U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07254611) titled 'Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations' on Nov. 17.
Brief Summary: Acute Myeloid Leukemia requires intensive chemotherapy treatment, usually followed by an allogeneic bone marrow transplant to reduce the risk of relapse. However, in elderly patients, intensive treatment is often not a feasible option due to the high toxicity, which limits its use. Recently, a combination of hypomethylating agents (HMAs, 5-azacitidine or decitabine), which have a low toxicity profile, and venetoclax, a potent inhibitor of the anti-apoptotic protein Bcl2, has been a...